{"denoms":[{"counts":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"97"},{"groupId":"BG003","value":"289"}],"units":"Participants"}],"groups":[{"description":"Placebo up to 6 cycles (1 cycle=28 days - median exposure= 24 weeks). At the end of cycle 6, participants were crossed-over to SAR302503 400 or 500 mg until disease progression or unacceptable toxicity.","id":"BG000","title":"Placebo"},{"description":"SAR302503 400 mg until disease progression and/or unacceptable toxicity (median exposure= 62.1 weeks).","id":"BG001","title":"SAR302503 400 mg"},{"description":"SAR302503 500 mg until disease progression and/or unacceptable toxicity (median exposure =59.7 weeks).","id":"BG002","title":"SAR302503 500 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.5","value":"64.9"},{"groupId":"BG001","spread":"9.6","value":"62.9"},{"groupId":"BG002","spread":"9.3","value":"64.7"},{"groupId":"BG003","spread":"9.5","value":"64.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"119"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"170"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}